Sarah Cavanaugh is VP at Celldex Therapeutics, Inc. (CLDX). They have made 5 open-market trades across 1 company since 2020, most recently 2024-05-30.
CIK 0001709113
1 open-market purchase totalling $5K since 2020, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CLDX | 1,860 | $51K |
Shares reported on the most recent Form 4, priced at the 2024-06-03 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CLDX | SELL | 2024-05-30 | 2024-06-03 | $33.73 | $1.4M | +10.8% | +9.2% | +26.2% |
| CLDX | SELL | 2022-08-17 | 2022-08-19 | $36.72 | $2.3M | -6.6% | -9.4% | +5.3% |
| CLDX | SELL | 2021-12-08 | 2021-12-10 | $40.00 | $293K | +10.5% | -2.9% | -13.6% |
| CLDX | SELL | 2021-11-01 | 2021-11-03 | $43.27 | $595K | -11.1% | -26.3% | -34.8% |
| CLDX | BUY | 2020-06-10 | 2020-06-11 | $4.83 | $5K | +34.8% | +23.2% | +32.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.